ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Dermatology · Br J Dermatol · 2026-07-17

Phase II trial in 94 patients with alopecia areata: deucravacitinib 6 mg once or twice daily vs placebo showed no meaningful difference in SALT score change at week 24 (adjusted differences 1.5 and 8.2) or secondary endpoints; efficacy endpoints were not met.

RCTn = 94
King et al. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicentre, randomized, double-blinded, placebo-controlled trial
Dermatology · J Am Acad Dermatol · 2025-11-27

Phase 3 trial in 517 adults with severe chronic alopecia areata: at week 24, SALT score ≤20 was reached by 33.0% on deuruxolitinib 8 mg BID and 38.3% on 12 mg BID vs 0.8% on placebo (P<.0001). Most drug-related adverse events were mild or moderate.

RCTn = 517
Tsianakas et al. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.